drugsProductApproved

Mesna

aka Uromitexan, Sodium 2-mercaptoethanesulfonate

Mesna is given with the chemotherapy ifosfamide (and high-dose cyclophosphamide) to stop its breakdown products from burning the bladder lining and causing bleeding.

Mesna was approved in December 1988 as a prophylactic agent to reduce the incidence of ifosfamide-induced haemorrhagic cystitis, with oral tablets approved in 2002 allowing intravenous-then-oral schedules; it is given with every ifosfamide dose (sarcoma, germ cell, lymphoma regimens such as ICE and VeIP) and with high-dose cyclophosphamide in transplant conditioning. The label notes it does not prevent haematuria from other causes such as thrombocytopenia. Hypersensitivity reactions, including rare severe skin reactions, and false-positive urine ketone tests are the practical issues; nausea and headache are common.

How supportive care & survivorship works, step by step · animated schematic, not to scale; chosen from the modality "Uroprotective thiol"

Supportive Care & Survivorship →

Modality

Uroprotective thiol

Mechanism

Free thiol excreted in urine that binds and detoxifies acrolein and 4-hydroxy-ifosfamide, the urotoxic metabolites of ifosfamide and cyclophosphamide, in the bladder.

Brand / code

Mesnex

Regulatory

1top

Approvals

Region	Year	Indication
US	1988	Prophylaxis of ifosfamide-induced haemorrhagic cystitis (oral tablets 2002)

Trials

top

ClinicalTrials.gov · phase 2/3

refreshed 2026-09-10

256 studies13 recruiting90 Phase 217 Phase 3

Search “Mesna” on ClinicalTrials.gov →

Counts are from a name search and may include unrelated studies; up to 100 studies are summarised.

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov

Mesna

intervention: Mesna

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.